Predicting Arrhythmic Risk in Arrhythmogenic Right Ventricular Cardiomyopathy: A Systematic Review and Meta-analysis
Overview
Authors
Affiliations
While many studies evaluate predictors of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy (ARVC), a systematic review consolidating this evidence is currently lacking. Therefore, we searched MEDLINE and Embase for studies analyzing predictors of ventricular arrhythmias (sustained ventricular tachycardia/fibrillation (VT/VF), appropriate implantable cardioverter-defibrillator therapy, or sudden cardiac death) in patients with definite ARVC, patients with borderline ARVC, and ARVC-associated mutation carriers. In the case of multiple publications on the same cohort, the study with the largest population was included. This yielded 45 studies with a median cohort size of 70 patients (interquartile range 60 patients) and a median follow-up of 5.0 years (interquartile range 3.3 - 6.7 years). The average proportion of arrhythmic events observed was 10.6%/y in patients with definite ARVC, 10.0%/y in patients with borderline ARVC, and 3.7%/y with mutation carriers. Predictors of ventricular arrhythmias were population dependent: consistently predictive risk factors in patients with definite ARVC were male sex, syncope, T-wave inversion in lead >V, right ventricular dysfunction, and prior (non)sustained VT/VF; in patients with borderline ARVC, 2 additional predictors-inducibility during electrophysiology study and strenuous exercise-were identified; and with mutation carriers, all aforementioned predictors as well as ventricular ectopy, multiple ARVC-related pathogenic mutations, left ventricular dysfunction, and palpitations/presyncope determined arrhythmic risk. Most evidence originated from small observational cohort studies, with a moderate quality of evidence. In conclusion, the average risk of ventricular arrhythmia ranged from 3.7 to 10.6%/y depending on the population with ARVC. Male sex, syncope, T-wave inversion in lead >V, right ventricular dysfunction, and prior (non)sustained VT/VF consistently predict ventricular arrhythmias in all populations with ARVC.
Clinical features and outcomes in carriers of pathogenic desmoplakin variants.
Gasperetti A, Carrick R, Protonotarios A, Murray B, Laredo M, van der Schaaf I Eur Heart J. 2024; 46(4):362-376.
PMID: 39288222 PMC: 11745529. DOI: 10.1093/eurheartj/ehae571.
A Territory-Wide Study of Arrhythmogenic Right Ventricular Cardiomyopathy Patients from Hong Kong.
Lakhani I, Zhou J, Lee S, Li K, Leung K, Hui J Rev Cardiovasc Med. 2024; 23(7):231.
PMID: 39076921 PMC: 11266799. DOI: 10.31083/j.rcm2307231.
The Challenges of Diagnosis and Treatment of Arrhythmogenic Cardiomyopathy: Are We there yet?.
Spadotto A, Morabito D, Carecci A, Massaro G, Statuto G, Angeletti A Rev Cardiovasc Med. 2024; 23(8):283.
PMID: 39076647 PMC: 11266951. DOI: 10.31083/j.rcm2308283.
Cardiomyopathy and Sudden Cardiac Death: Bridging Clinical Practice with Cutting-Edge Research.
Mistrulli R, Ferrera A, Salerno L, Vannini F, Guida L, Corradetti S Biomedicines. 2024; 12(7).
PMID: 39062175 PMC: 11275154. DOI: 10.3390/biomedicines12071602.
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers.
Carrick R, Gasperetti A, Protonotarios A, Murray B, Laredo M, van der Schaaf I Eur Heart J. 2024; 45(32):2968-2979.
PMID: 39011630 PMC: 11335372. DOI: 10.1093/eurheartj/ehae409.